Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETX-19477 in Advanced Solid Malignancies
NCT06395519Phase 2Recruiting
- Sponsor
- 858 Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ETX-19477 in solid tumor, breast cancer, ovarian cancer, prostate cancer (PCa), endometrial cancer (EC), sponsored by 858 Therapeutics. Started May 2024; status: recruiting.
02
Drugs
ETX-19477
03
Conditions
solid tumorbreast cancerovarian cancerprostate cancer (PCa)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06395519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395519.